Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly

H. T. Kiziltan, D. A. Theodoro, C. A. Warnes, P. W. O'Leary, B. J. Anderson, G. K. Danielson, A. F. Carpentier, I. A. Ozdemir

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Background. Historically, porcine bioprosthetic valves have poor durability in pediatric patients; nearly half will require replacement within 5 years. However, our early experience with patients having Ebstein's anomaly suggests that tricuspid bioprostheses in this anomaly might have better durability. Methods. One hundred fifty-eight patients who received a primary tricuspid bioprosthesis because of tricuspid valve anatomy unsuitable for repair between April 1972 and January 1997 were reviewed. Results were analyzed and Kaplan-Meier curves were constructed to estimate patient survival and probability of remaining free of reoperation. Results. Follow- up of 149 patients (94.3%) who survived 30 days ranged up to 17.8 years (mean, 4.5 years). Ten-year survival was 92.5% ± 2.5% (SE), 129 late survivors (92.1%) were in New York Heart Association class I or II, and 93.6% were free of anticoagulation. Freedom from bioprosthesis replacement was 97.5% ± 1.9% at 5 years and 80.6% ± 7.6% at 10 and 15 years. Conclusions. Bioprosthesis durability in the tricuspid position in patients with Ebstein's anomaly compares very favorably with bioprosthesis durability in other cardiac valve positions, especially for pediatric patients, and also compares favorably with tricuspid bioprosthesis durability in patients with other diagnoses.

Original languageEnglish (US)
Pages (from-to)1539-1545
Number of pages7
JournalAnnals of Thoracic Surgery
Volume66
Issue number5
DOIs
StatePublished - 1998

Fingerprint

Ebstein Anomaly
Tricuspid Valve
Bioprosthesis
Pediatrics
Survival
Heart Valves
Reoperation
Survivors
Anatomy
Swine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Kiziltan, H. T., Theodoro, D. A., Warnes, C. A., O'Leary, P. W., Anderson, B. J., Danielson, G. K., ... Ozdemir, I. A. (1998). Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly. Annals of Thoracic Surgery, 66(5), 1539-1545. https://doi.org/10.1016/S0003-4975(98)00961-8

Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly. / Kiziltan, H. T.; Theodoro, D. A.; Warnes, C. A.; O'Leary, P. W.; Anderson, B. J.; Danielson, G. K.; Carpentier, A. F.; Ozdemir, I. A.

In: Annals of Thoracic Surgery, Vol. 66, No. 5, 1998, p. 1539-1545.

Research output: Contribution to journalArticle

Kiziltan, HT, Theodoro, DA, Warnes, CA, O'Leary, PW, Anderson, BJ, Danielson, GK, Carpentier, AF & Ozdemir, IA 1998, 'Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly', Annals of Thoracic Surgery, vol. 66, no. 5, pp. 1539-1545. https://doi.org/10.1016/S0003-4975(98)00961-8
Kiziltan HT, Theodoro DA, Warnes CA, O'Leary PW, Anderson BJ, Danielson GK et al. Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly. Annals of Thoracic Surgery. 1998;66(5):1539-1545. https://doi.org/10.1016/S0003-4975(98)00961-8
Kiziltan, H. T. ; Theodoro, D. A. ; Warnes, C. A. ; O'Leary, P. W. ; Anderson, B. J. ; Danielson, G. K. ; Carpentier, A. F. ; Ozdemir, I. A. / Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly. In: Annals of Thoracic Surgery. 1998 ; Vol. 66, No. 5. pp. 1539-1545.
@article{aff3ca27a4d1465599cda23b5003b6a3,
title = "Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly",
abstract = "Background. Historically, porcine bioprosthetic valves have poor durability in pediatric patients; nearly half will require replacement within 5 years. However, our early experience with patients having Ebstein's anomaly suggests that tricuspid bioprostheses in this anomaly might have better durability. Methods. One hundred fifty-eight patients who received a primary tricuspid bioprosthesis because of tricuspid valve anatomy unsuitable for repair between April 1972 and January 1997 were reviewed. Results were analyzed and Kaplan-Meier curves were constructed to estimate patient survival and probability of remaining free of reoperation. Results. Follow- up of 149 patients (94.3{\%}) who survived 30 days ranged up to 17.8 years (mean, 4.5 years). Ten-year survival was 92.5{\%} ± 2.5{\%} (SE), 129 late survivors (92.1{\%}) were in New York Heart Association class I or II, and 93.6{\%} were free of anticoagulation. Freedom from bioprosthesis replacement was 97.5{\%} ± 1.9{\%} at 5 years and 80.6{\%} ± 7.6{\%} at 10 and 15 years. Conclusions. Bioprosthesis durability in the tricuspid position in patients with Ebstein's anomaly compares very favorably with bioprosthesis durability in other cardiac valve positions, especially for pediatric patients, and also compares favorably with tricuspid bioprosthesis durability in patients with other diagnoses.",
author = "Kiziltan, {H. T.} and Theodoro, {D. A.} and Warnes, {C. A.} and O'Leary, {P. W.} and Anderson, {B. J.} and Danielson, {G. K.} and Carpentier, {A. F.} and Ozdemir, {I. A.}",
year = "1998",
doi = "10.1016/S0003-4975(98)00961-8",
language = "English (US)",
volume = "66",
pages = "1539--1545",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Late results of bioprosthetic tricuspid valve replacement in Ebstein's anomaly

AU - Kiziltan, H. T.

AU - Theodoro, D. A.

AU - Warnes, C. A.

AU - O'Leary, P. W.

AU - Anderson, B. J.

AU - Danielson, G. K.

AU - Carpentier, A. F.

AU - Ozdemir, I. A.

PY - 1998

Y1 - 1998

N2 - Background. Historically, porcine bioprosthetic valves have poor durability in pediatric patients; nearly half will require replacement within 5 years. However, our early experience with patients having Ebstein's anomaly suggests that tricuspid bioprostheses in this anomaly might have better durability. Methods. One hundred fifty-eight patients who received a primary tricuspid bioprosthesis because of tricuspid valve anatomy unsuitable for repair between April 1972 and January 1997 were reviewed. Results were analyzed and Kaplan-Meier curves were constructed to estimate patient survival and probability of remaining free of reoperation. Results. Follow- up of 149 patients (94.3%) who survived 30 days ranged up to 17.8 years (mean, 4.5 years). Ten-year survival was 92.5% ± 2.5% (SE), 129 late survivors (92.1%) were in New York Heart Association class I or II, and 93.6% were free of anticoagulation. Freedom from bioprosthesis replacement was 97.5% ± 1.9% at 5 years and 80.6% ± 7.6% at 10 and 15 years. Conclusions. Bioprosthesis durability in the tricuspid position in patients with Ebstein's anomaly compares very favorably with bioprosthesis durability in other cardiac valve positions, especially for pediatric patients, and also compares favorably with tricuspid bioprosthesis durability in patients with other diagnoses.

AB - Background. Historically, porcine bioprosthetic valves have poor durability in pediatric patients; nearly half will require replacement within 5 years. However, our early experience with patients having Ebstein's anomaly suggests that tricuspid bioprostheses in this anomaly might have better durability. Methods. One hundred fifty-eight patients who received a primary tricuspid bioprosthesis because of tricuspid valve anatomy unsuitable for repair between April 1972 and January 1997 were reviewed. Results were analyzed and Kaplan-Meier curves were constructed to estimate patient survival and probability of remaining free of reoperation. Results. Follow- up of 149 patients (94.3%) who survived 30 days ranged up to 17.8 years (mean, 4.5 years). Ten-year survival was 92.5% ± 2.5% (SE), 129 late survivors (92.1%) were in New York Heart Association class I or II, and 93.6% were free of anticoagulation. Freedom from bioprosthesis replacement was 97.5% ± 1.9% at 5 years and 80.6% ± 7.6% at 10 and 15 years. Conclusions. Bioprosthesis durability in the tricuspid position in patients with Ebstein's anomaly compares very favorably with bioprosthesis durability in other cardiac valve positions, especially for pediatric patients, and also compares favorably with tricuspid bioprosthesis durability in patients with other diagnoses.

UR - http://www.scopus.com/inward/record.url?scp=0032433705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032433705&partnerID=8YFLogxK

U2 - 10.1016/S0003-4975(98)00961-8

DO - 10.1016/S0003-4975(98)00961-8

M3 - Article

C2 - 9875748

AN - SCOPUS:0032433705

VL - 66

SP - 1539

EP - 1545

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -